Clinical Trial Update: A Study of SHR-2173 in Participants With Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

This entry provides a Phase 2 clinical trial update for SHR-2173 in primary IgA nephropathy, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• SHR-2173

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Primary IgA Nephropathy | Phase 2 | Status: NOT_YET_RECRUITING